Trevi Therapeutics, Inc. (TRVI)
| Market Cap | 617.59M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -47.35M |
| Shares Out | 101.74M |
| EPS (ttm) | -0.44 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,432,336 |
| Open | 6.12 |
| Previous Close | 6.12 |
| Day's Range | 5.98 - 6.24 |
| 52-Week Range | 2.36 - 7.48 |
| Beta | 0.53 |
| Analysts | Strong Buy |
| Price Target | 19.31 (+218.12%) |
| Earnings Date | Aug 7, 2025 |
About TRVI
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of investigational therapy for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung disease, and refractory chronic cough. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER clinical trial for treatment of chronic cough in patients with IPF; phase 2 clinical trial in pat... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for TRVI stock is "Strong Buy." The 12-month stock price forecast is $19.31, which is an increase of 218.12% from the latest price.
News
Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
NEW HAVEN, Conn. , June 5, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER)...
Trevi Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock
NEW HAVEN, Conn. , June 3, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER)...
Trevi Therapeutics Announces Proposed Public Offering of Common Stock
NEW HAVEN, Conn. , June 2, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER)...
Trevi Therapeutics Showcases Drug That Cuts Cough Frequency In Lung Disease Patients
Trevi Therapeutics, Inc. TRVI revealed topline results on Monday from its Phase 2b CORAL trial of Haduvio for chronic cough in patients with idiopathic pulmonary fibrosis (IPF) (N=165).
Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough
Haduvio met the primary endpoint with statistically-significant reductions in 24-hour cough frequency across all dose groups (108 and 54 mg BID p
Trevi Therapeutics to Host Conference Call and Webcast on June 2nd to Share Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough
Conference call and webcast to be held at 8:30 a.m. ET NEW HAVEN, Conn.
Trevi Therapeutics to Participate in Upcoming June Conferences
NEW HAVEN, Conn. , May 29, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER...
Trevi Therapeutics Announces Additional Analyses from Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough
Results of analyses presented at an investor meeting during the American Thoracic Society 2025 International Conference NEW HAVEN, Conn. , May 20, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq...
Trevi Therapeutics, Inc. (TRVI) Q1 2025 Earnings Call Transcript
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Jennifer Good - Co-Founder, President and Chief Executive Officer Lisa Delfini - Ch...
Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates
Completed enrollment and last patient last visit in the Phase 2b CORAL trial in IPF patients with chronic cough; topline results continue to be expected in the second quarter of 2025 Announced positiv...
Trevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025
Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn.
Trevi Therapeutics to Participate in Upcoming April Investor Conferences
NEW HAVEN, Conn. , April 3, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER...
Trevi Therapeutics, Inc. (TRVI) Q4 2024 Earnings Call Transcript
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2024 Earnings Conference Call March 18, 2025 4:30 PM ET Company Participants Jennifer Good - Co-Founder, President and Chief Executive Officer Lisa Delfini -...
Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates
Announced positive topline data from the Phase 2a RIVER trial in patients with refractory chronic cough (RCC), making Haduvio the first therapy in clinical development to show benefit in patients with...
Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025
Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn.
Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps
On Monday, Trevi Therapeutics, Inc. TRVI reported topline results from its Phase 2a RIVER trial of Haduvio (oral nalbuphine ER) for the treatment of patients with refractory chronic cough (N=66).
Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough
Haduvio met the primary endpoint with a statistically-significant reduction (p
Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough
Conference call and webcast to be held at 8:30 a.m. ET NEW HAVEN, Conn.
Trevi Therapeutics to Participate in Upcoming March Investor Conferences
NEW HAVEN, Conn. , Feb. 27, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER...
Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough
Topline results continue to be expected in the first half of 2025 NEW HAVEN, Conn. , Feb. 25, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company ...
Trevi Therapeutics to Participate in Upcoming February Investor Conferences
NEW HAVEN, Conn. , Jan. 30, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ...
Trevi Therapeutics Announces Company Updates Ahead of 14th Annual LifeSci Partners Corporate Access Event Held During the J.P. Morgan Healthcare Conference
Last patient completed the Phase 2a RIVER trial in refractory chronic cough (RCC) in early January and topline results continue to be expected in the first quarter of 2025 Approximately 80% of enrollm...
Trevi Therapeutics Announces Pricing of $50 Million Underwritten Offering
NEW HAVEN, Conn. , Dec. 16, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy, Haduvio™ (oral nalbuphine E...
Why Is Cough-Focused Trevi Therapeutics Stock Skyrocketing On Thursday?
On Thursday, Trevi Therapeutics, Inc. TRVI announced the outcome from the planned sample size re-estimation (SSRE) for the ongoing Phase 2b CORAL trial in idiopathic pulmonary fibrosis (IPF) patients ...
Trevi Therapeutics Announces Positive Outcome from Sample Size Re-estimation Resulting in No Change to the Current Sample Size for the Phase 2b CORAL Trial in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough
Independent Data Monitoring Statistician reaffirmed current sample size to remain at N=160 The trial has reached 75% of the targeted enrollment, and topline results continue to be expected in the firs...